The Global Immunohistochemistry Industry is poised for steady growth, according to industry projections. Valued at an estimated US$3.5 billion in 2024, the market is expected to reach US$7.4 billion by 2034, reflecting a moderate Compound Annual Growth Rate (CAGR) of 7.8% over the forecast period. This growth is indicative of the increasing adoption of IHC techniques in various applications.
Pathology and molecular biology both make extensive use of the method of immunohistochem istry to reveal important details about cellular makeup, operations, and pathological states. So, immunohistochemistry is widely used in biomedical research in several fields, including cancer research, medication development, and diagnostic pathology.
The effectiveness and precision of immunohistochemistry have increased through technological and automated improvements making it affordable and practical for a range of clinical applications. Furthermore, the procedure has been streamlined, and turnaround time has been decreased, with automated platforms, multiplex staining methods, and digital imaging systems.
Demand for biomarker evaluation is expanding with the increased focus on targeted medicines and the requirement for accurate patient categorization based on molecular profiling. So, it is anticipated that the need for immunohistochemistry -based diagnostics might be driven by the growing elderly population vulnerable to chronic illnesses. On top of that, the market is expanding as a result of rising awareness of early illness detection and the value of correct diagnosis.
Request a sample report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-14808
Key Takeaways from the Global Immunohistochemistry Industry Study Report
- Geographically, the United States controlled 38.8% of the global market in 2022 because of the region’s developed healthcare infrastructure, and high healthcare spending.
- The demand for immunohistochemistry-based diagnostics in the United Kingdom is being fueled by the rising prevalence of chronic illnesses and the growing elderly population. However, over the next ten years, this regional market is anticipated to witness an annual average growth rate of only 3.9%.
- FMI projects that the Asia Pacific region could see substantial development in the adoption of immunohistochemistry, mostly because of the region’s expanding healthcare infrastructure. Particularly, China and India have increased investments in the biotechnology and pharmaceutical industries, and are expected to witness 9.3% and 8.7% CAGRs through 2033 respectively.
Competitive Landscape and Recent Developments by the Immunohistochemistry Service Providers
- The debut of Abcam, PLC’s new line of immunohistochemistry primary antibodies was announced in June 2023. The company claims the purpose of these antibodies is to enhance the identification of particular proteins in tissue samples.
- A new series of automated immunohistochemistry kits from DakoEnVision Company was introduced by Merck KGaA in May 2023. These improved kits are designed and intended to increase the IHC testing’s sensitivity and specificity.
- Agilent Technologies Incorporation, a manufacturer of automated immunohistochemistry systems, announced in March 2023 that it had acquired Amnis Corporation. Agilent now can access new customers and diversify its IHC product line after this purchase.
- Thermo Fisher Scientific Incorporation declared the release of their new PathXL immunohistochemistry software in April 2023. This new program is intended to make it easy for pathologists to correctly interpret immunohistochemistry data.
- Hoffmann-La Roche AG declared the release of its brand-new Ventana Benchmark XT automated IHC system in February 2023. The system’s prominent role is to increase the precision and effectiveness of immunohistochemistry diagnostics or testing.
- Thermo Fisher, F. Hoffmann-La Roche, Merck, Danaher, PerkinElmer, Bio-Rad Laboratories, Bio SB, Agilent Technologies, and Abcam are some top service providers in this market.
Ask an Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-14808
Global Immunohistochemistry Industry Key Segmentation
By Product:
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Slide Staining System
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological stains
- Blocking Sera and Reagents
- Chromogenic Substrates
- Fixation Reagents
- Stabilizers
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Kits
By Application:
- Diagnostics
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Diabetes Mellitus
- Nephrological Diseases
- Drug Testing
By End Use:
- Hospitals & Diagnostic Laboratories
- Research Institutes
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacifica
- The Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube